Literature DB >> 8724813

Mechanism of action of streptogramins and macrolides.

P Vannuffel1, C Cocito.   

Abstract

Protein synthesis is catalysed by ribosomes and cytoplasmic factors. Bacterial ribosomes (70S) are made up of 2 subunits (50S and 30S) containing ribosomal RNA (rRNA) and ribosomal proteins: the 30S binds messenger RNA and begins the ribosomal cycle (initiation), whereas 50S binds transfer RNA (tRNA) derivatives and controls elongation. The key reaction, peptide bond formation, is promoted by the catalytic centre of 50S (the peptidyl transferase centre), and the growing peptide chain (peptidyl-tRNA) attached at the donor P site undergoes peptide linkage with an aminoacyl-tRNA at the acceptor A site. This reaction is inhibited by several antibiotics, the best known being chloramphenicol, and the macrolide-lincosamide-streptogramin (MLS) group. These inhibitors have a reversible action, except for streptogramins that are composed of A and B components, which are bacteriostatic alone, but bactericidal when combined. The peptidyl transferase centre has been identified at the 50S surface, and the binding sites of inhibitors have been mapped within this domain: some of these sites overlap (e.g. those of macrolides, and type B streptogramins, which compete for binding to ribosomes). Chloramphenicol blocks the catalytic portion, and A streptogramins the substrate sites of the peptidyl transferase centre. Macrolides and type B streptogramins interfere with the formation of long polypeptides and cause a premature detachment of incomplete peptide chains. The synergism between types A and B streptogramins is due to induction by type A streptogramins of an increased ribosome affinity for type B streptogramins. Microbial resistance to antibiotics mainly involves inactivation of inhibitors and modification of targets (mutations of ribosomal proteins or rRNA genes). Alterations of rRNA bases can induce resistance to a single inhibitor or to a group of antibiotics (e.g. MLSB). The impact of resistance in chemotherapy is less important for streptogramins than for other inhibitors, because the synergistic effect of A and B streptogramins also applies to strains resistant to the MLSB group. It is proposed that mutations and modifications of rRNA bases induce conformational ribosomal changes that prevent antibiotics binding to the target. Conformational changes are also triggered by type A streptogramins: they are responsible for their synergism with type B streptogramins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724813     DOI: 10.2165/00003495-199600511-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  18 in total

1.  Identification of a single base change in ribosomal RNA leading to erythromycin resistance.

Authors:  P Vannuffel; M Di Giambattista; E A Morgan; C Cocito
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

2.  The role of rRNA bases in the interaction of peptidyltransferase inhibitors with bacterial ribosomes.

Authors:  P Vannuffel; M Di Giambattista; C Cocito
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

Review 3.  Ribosomal RNA and translation.

Authors:  H F Noller
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

4.  Analysis of the reversible binding of virginiamycin M to ribosome and particle functions after removal of the antibiotic.

Authors:  E Nyssen; M Di Giambattista; C Cocito
Journal:  Biochim Biophys Acta       Date:  1989-09-21

5.  Localization of virginiamycin S binding site on bacterial ribosome by fluorescence energy transfer.

Authors:  M Di Giambattista; A P Thielen; J A Maassen; W Möller; C Cocito
Journal:  Biochemistry       Date:  1986-06-17       Impact factor: 3.162

Review 6.  On the nature of antibiotic binding sites in ribosomes.

Authors:  E Cundliffe
Journal:  Biochimie       Date:  1987-08       Impact factor: 4.079

7.  Action of virginiamycin M on the stability of different ribosomal complexes to ultracentrifugation.

Authors:  G Chinali; F Vanlinden; C Cocito
Journal:  Biochim Biophys Acta       Date:  1988-05-06

8.  The action of virginiamycin M on the acceptor, donor, and catalytic sites of peptidyltransferase.

Authors:  G Chinali; P Moureau; C G Cocito
Journal:  J Biol Chem       Date:  1984-08-10       Impact factor: 5.157

9.  Molecular mechanism of action of virginiamycin-like antibiotics (synergimycins) on protein synthesis in bacterial cell-free systems.

Authors:  C Cocito; G Chinali
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

10.  Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA.

Authors:  D Moazed; H F Noller
Journal:  Biochimie       Date:  1987-08       Impact factor: 4.079

View more
  20 in total

1.  Quinupristin-dalfopristin is active against Toxoplasma gondii.

Authors:  A A Khan; T R Slifer; F G Araujo; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  Ribosome-targeting antibiotics and mechanisms of bacterial resistance.

Authors:  Daniel N Wilson
Journal:  Nat Rev Microbiol       Date:  2014-01       Impact factor: 60.633

3.  In vitro activities of quinupristin-dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae.

Authors:  K Izumikawa; Y Hirakata; T Yamaguchi; R Yoshida; H Tanaka; H Takemura; S Maesaki; K Tomono; M Kaku; K I Izumikawa; S Kamihira; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 4.  How antibiotics kill bacteria: from targets to networks.

Authors:  Michael A Kohanski; Daniel J Dwyer; James J Collins
Journal:  Nat Rev Microbiol       Date:  2010-05-04       Impact factor: 60.633

Review 5.  NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA.

Authors:  Amani D Politano; Robert G Sawyer
Journal:  Curr Opin Investig Drugs       Date:  2010-02

6.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Anne Theunis; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 7.  Streptogramins and their potential role in geriatric medicine.

Authors:  B M Lomaestro; L L Briceland
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

8.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

9.  Susceptibility of Propionibacterium acnes isolated from patients with acne vulgaris to zinc ascorbate and antibiotics.

Authors:  Katsuhiro Iinuma; Norihisa Noguchi; Hidemasa Nakaminami; Masanori Sasatsu; Setsuko Nishijima; Isami Tsuboi
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-10-05

Review 10.  Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.

Authors:  Charles W Stratton
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.